On Tuesday, Compass Therapeutics Inc (NASDAQ: CMPX) opened higher 14.18% from the last session, before settling in for the closing price of $2.82. Price fluctuations for CMPX have ranged from $0.76 to $3.13 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -6.06% at the time writing. With a float of $83.22 million, this company’s outstanding shares have now reached $137.59 million.
The firm has a total of 32 workers. Let’s measure their productivity. In terms of profitability, gross margin is 74.8%, operating margin of -1501.0%, and the pretax margin is -1292.88%.
Compass Therapeutics Inc (CMPX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Compass Therapeutics Inc is 39.51%, while institutional ownership is 43.49%.
Compass Therapeutics Inc (CMPX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.60% during the next five years compared to 12.88% growth over the previous five years of trading.
Compass Therapeutics Inc (NASDAQ: CMPX) Trading Performance Indicators
Check out the current performance indicators for Compass Therapeutics Inc (CMPX). In the past quarter, the stock posted a quick ratio of 31.84. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 521.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.40 in one year’s time.
Technical Analysis of Compass Therapeutics Inc (CMPX)
Analysing the last 5-days average volume posted by the [Compass Therapeutics Inc, CMPX], we can find that recorded value of 2.25 million was lower than the volume posted last year of 3.08 million. As of the previous 9 days, the stock’s Stochastic %D was 75.95%. Additionally, its Average True Range was 0.31.
During the past 100 days, Compass Therapeutics Inc’s (CMPX) raw stochastic average was set at 91.55%, which indicates a significant increase from 90.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 177.84% in the past 14 days, which was higher than the 103.10% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.76, while its 200-day Moving Average is $1.51. Now, the first resistance to watch is $3.46. This is followed by the second major resistance level at $3.69. The third major resistance level sits at $3.99. If the price goes on to break the first support level at $2.93, it is likely to go to the next support level at $2.63. Now, if the price goes above the second support level, the third support stands at $2.40.
Compass Therapeutics Inc (NASDAQ: CMPX) Key Stats
There are currently 137,589K shares outstanding in the company with a market cap of 443.04 million. Presently, the company’s annual sales total 0 K according to its annual income of -42,490 K. Last quarter, the company’s sales amounted to 850 K and its income totaled -13,080 K.
